GLENMARK Intraday Analysis...

GLENMARK Share Price

Open 888.00 Change Price %
High 898.85 1 Day 11.20 1.27
Low 885.80 1 Week -0.65 -0.07
Close 895.50 1 Month -37.95 -4.07
Volume 494314 1 Year 73.65 8.96
52 Week High 994.00
52 Week Low 730.00
GLENMARK Important Levels
Resistance 2 907.60
Resistance 1 902.61
Pivot 893.38
Support 1 888.39
Support 2 883.40
NSE INDIA Most Active Stocks
SUZLON 19.00 3.54%
IDEA 91.60 0.33%
JPASSOCIAT 13.35 1.14%
HINDZINC 319.55 2.47%
ITC 277.60 -0.80%
ITC 277.60 -0.80%
VIKASECO 21.80 7.39%
BEPL 28.55 11.96%
VEDL 265.70 1.76%
IDFC 53.25 0.00%
More..
NSE INDIA Top Gainers Stocks
VKSPL 0.10 100.00%
FARMAXIND 0.10 100.00%
VISESHINFO 0.25 25.00%
SDBL 144.30 20.00%
RAJRAYON 0.30 20.00%
ITI 68.70 20.00%
ITI 68.70 20.00%
CIMMCO 74.30 19.94%
MANAKCOAT 10.55 19.89%
LAKPRE 44.00 19.89%
More..
NSE INDIA Top Losers Stocks
AUSTRAL 0.25 -16.67%
NTL 5.75 -15.44%
NTL 5.75 -15.44%
PGIL 116.95 -10.96%
SPYL 0.45 -10.00%
GALLISPAT 449.50 -9.32%
ALANKIT 17.95 -7.47%
ARCOTECH 503.20 -6.94%
COMPINFO 37.50 -6.25%
POLYMED 544.35 -6.15%
More..

Glenmark Pharmaceuticals Limited (NSE: GLENMARK)

GLENMARK Technical Analysis 1.5
As on 23rd Mar 2017 GLENMARK Share Price closed @ 895.50 and we RECOMMEND Buy for LONG-TERM with Stoploss of 874.86 & Sell for SHORT-TERM with Stoploss of 909.66 we also expect STOCK to react on Following IMPORTANT LEVELS.
GLENMARK Target for March
1st Target up-side 975.89
2nd Target up-side 1011.2
3rd Target up-side 1046.52
1st Target down-side 875.11
2nd Target down-side 839.8
3rd Target down-side 804.48
GLENMARK Synopsis Technicals View
50 Day EMA Close is Below EMA 50 (Short Term)
Bearish
100 Day EMA Close is Below EMA 100 (Mid Term) Bearish
200 Day EMA Close is Above EMA 200 (Long Term) Bullish
MACD (12 26 9) MACD Line is Less Then SIGNAL Line Bearish
RSI (14) RSI is 46.20 Sideways
MFI (14) MFI is 46.77 Sideways
CCI (20) CCI is -49.41 Sideways
WILLIAM %R (14) William %R is -67.36 Sideways
ADX (14) ADX is 19.96 Range Bound
PSAR Stoploss For Short Sell 920.35
10 Day Avg Volume Traded -31.49 % Less then 10 Day Average Volume
GLENMARK Other Details
Segment EQ
Market Capital 68178259968.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.glenmarkpharma.com
GLENMARK Address
GLENMARK
Glenmark House
B D S Marg
Mumbai, 400099
India
Phone: 91 22 4018 9999
Fax: 91 22 4018 9990
GLENMARK Latest News
Interactive Technical Analysis Chart Glenmark Pharmaceuticals Limited ( GLENMARK NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Glenmark Pharmaceuticals Limited
GLENMARK Business Profile
Glenmark Pharmaceuticals (GPL) is engaged in the research and development, manufacturing and marketing of branded formulations in India and abroad. The company is headquartered at Mumbai and was incorporated in the year 1977 by Gracias Saldanha. Its business segments include India API, exports formulations and API NCE research. The company is present in over 80 countries across the globe, with some of its subsidiaries and representative offices in the United States, the United Kingdom, Switzerland, Brazil, South Africa, Nigeria, Russia, Philippines and Malaysia. It has been involved in new drug discoveries such as new molecules for asthma, obesity and diabetes segments. Glenmark has been involved in API business. Glenmark conducts its operations through its manufacturing plants including Baddi, Goa, Nasik and Sao Paulo, Brazil for formulations and Ankleshwar, Kurkumbh and Solapur for API. Glenmark Pharmaceuticals` research activities encompass process engineering for APIs, new chemical entity research and novel drug delivery systems [NDDS]. The company also operates a second research facility at Sinnar, India that focuses on developing formulations for India and markets across Asia, Africa, Latin America and CIS/Russia. The company is further researching PDE-4 inhibitors for CNS indications, cognitive disorders and inflammatory conditions such as atopic dermatitis, ulcerative colitis and rheumatoid arthritis. Other research areas include diabetes segment in which the company has a DPP-IV target, GRC 8200, in Phase I clinical trials. For the last five years the company has increased its growth through investment in dedicated research and development, including cutting-edge New Chemical Technology (NCE) research. The company currently ranks among the top 20 Indian pharmaceutical firms. The current market capitalization stands at Rs 13,855.67 crore. The company has reported a consolidated sales of Rs 1463.38 crore and a Net Profit of Rs 157.3 crore for the quarter ended September 2013. The company management includes Glenn Saldanha - Chairman & Managing Director, Rajesh V Desai - Executive Director & CFO, Cherylann Pinto - Director - Corporate Affairs, D R Mehta - Non Executive Director, Bernard Munos - Non Executive Director, J F Ribeiro - Non Executive Director, Brian W Tempest - Non Executive Director, Sridhar Gorthi - Non Executive Director, Hocine Sidi Said - Non Executive Director, N B Desai - Non Executive Director. The Registered office is at B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai,Maharashtra - 400026 and corporate office is at Glenmark House, HDO Corporate Building, Wing - A, B. D. Sawant Marg, Chakala, Off Western Express Highway, Andheri - E, Mumbai - 400099 in MAHARASHTRA.